Ruirong Tan

6PUBLICATIONS
8CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Solid tumoursTraditional Chinese medicine and treatments
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jun 09, 2026
SHP2 Inhibition Reveals Compensatory PI3K-AKT Activation in KRAS-Driven Pancreatic Cancer: Discovery of SDUY104 and Rational Approaches for Combination Therapy.

|Mar 13, 2025
IP6K2 mutations as a novel mechanism of resistance to oncolytic virus therapy.

Zhijian Huang, Xiangqian Zhao, Zirong Jiang

|Nov 18, 2024
Correction: Treating ICB-resistant cancer by inhibiting PD-L1 via DHHC3 degradation induced by cell penetrating peptide-induced chimera conjugates.

Yu-Ying Shi, Gang Fan, Ruirong Tan

|Sep 30, 2024
Treating ICB-resistant cancer by inhibiting PD-L1 via DHHC3 degradation induced by cell penetrating peptide-induced chimera conjugates.

Yu-Ying Shi, Gang Fan, Ruirong Tan

|Sep 27, 2024
Organoid modeling meets cancers of female reproductive tract.

Jiao Li, Mengting Zhou, Jun Xie

|Jun 05, 2024
The role of tetrahydrocurcumin in disease prevention and treatment.

Mengting Zhou, Rui Li, Hua Hua

Pageof 1

Frequent Collaborators

3 joint publications

Miao Liu

3 joint publications

Rui Li

2 joint publications

Hua-Bing Sun

2 joint publications

Meng-Yuan Dai